ICD10 code of Malignant hyperthermia and ICD9 code

The ICD-10 code for Malignant hyperthermia is T88.3 (Malignant hyperthermia due to anesthesia), while the legacy ICD-9 code is 995.86. These codes are essential for medical billing and clinical documentation to ensure patients receive appropriate monitoring and specialized care during surgical procedures.

What is the clinical significance of Malignant hyperthermia?

Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder of skeletal muscle that usually manifests during or after exposure to volatile anesthetic gases or the depolarizing muscle relaxant succinylcholine. In individuals with Malignant hyperthermia, these triggering agents cause an uncontrolled release of calcium from the sarcoplasmic reticulum, leading to a hypermetabolic state. This state results in muscle rigidity, rapid heart rate (tachycardia), high fever (hyperthermia), and the breakdown of muscle tissue (rhabdomyolysis). Recognizing the triggers for Malignant hyperthermia is critical for surgical safety, as prompt administration of the antidote, dantrolene, is life-saving.

Is Malignant hyperthermia hereditary?

Yes, Malignant hyperthermia is a genetic condition typically inherited in an autosomal dominant pattern. This means that an individual only needs to inherit the pathogenic variant from one parent to be at risk. The most common genetic cause is a mutation in the RYR1 gene, which encodes the ryanodine receptor. Because Malignant hyperthermia can be passed down through families, it is vital for relatives of a diagnosed patient to undergo genetic counseling and, if necessary, clinical evaluation to determine their own risk profile before undergoing any surgery involving anesthesia.

How is a diagnosis of Malignant hyperthermia confirmed?

Diagnosis of Malignant hyperthermia is multifaceted and often relies on a combination of clinical history and specialized testing. Because the condition is often "silent" until a crisis occurs, clinicians look for the following indicators:

• Clinical presentation: Unexplained high fever, muscle rigidity (specifically masseter spasm), and tachycardia during anesthesia.


• Caffeine-Halothane Contracture Test (CHCT): The gold standard diagnostic test, where a muscle biopsy is taken and exposed to caffeine and halothane to observe the muscle's contractile response.


• Genetic Testing: Molecular genetic testing for RYR1 mutations, which can identify the risk without the need for an invasive biopsy, though a negative result does not definitively rule out the condition.

Living with the diagnosis and community support

Receiving a diagnosis of Malignant hyperthermia can be overwhelming, as it necessitates constant vigilance regarding medical procedures. At DiseaseMaps.org, 42 people with Malignant hyperthermia have joined our community, sharing their experiences with medical alert bracelets, anesthesiology consultations, and navigating the healthcare system. Connecting with others who understand the reality of living with this condition can provide significant emotional support and practical tips for communicating your status to healthcare providers.

Next steps

• Consult with a board-certified anesthesiologist to discuss your specific genetic risk before any scheduled surgery.


• Wear a medical alert bracelet or carry a card clearly stating your Malignant hyperthermia status at all times.


• Visit the Malignant Hyperthermia Association of the United States (MHAUS) website to access resources for patients and families.


• Join the community at DiseaseMaps.org to share your journey and learn from the experiences of 42 other members living with this condition.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Malignant hyperthermia (ORPHA:399)


• NIH Genetic and Rare Diseases Information Center (GARD): Malignant hyperthermia


• Malignant Hyperthermia Association of the United States (MHAUS): Patient Resources


• OMIM (Online Mendelian Inheritance in Man): Malignant Hyperthermia, Susceptibility to (Entry #145600)